Home/Rare Diseases/Merkel Cell Carcinoma

Rare Cancers

Merkel Cell Carcinoma (MCC) Clinical Trials and Treatments

Also called MCC, neuroendocrine carcinoma of the skin, trabecular carcinoma

Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer with aggressive behavior and high recurrence rates. It arises from Merkel cells, specialized mechanoreceptors in the basal layer of the epidermis.

View 42 active trialsMatch me to a trial

About Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer with aggressive behavior and high recurrence rates. It arises from Merkel cells, specialized mechanoreceptors in the basal layer of the epidermis. MCC is associated with two distinct etiologic pathways: Merkel cell polyomavirus (MCPyV) integration (80% of cases) and ultraviolet radiation-induced DNA damage (virus-negative MCC, which typically has very high mutational burden).

MCC typically presents as a rapidly growing, painless, dome-shaped nodule on sun-exposed skin. The mnemonic AEIOU describes its features: Asymptomatic, Expanding rapidly, Immune suppression, Older age, UV-exposed skin. Despite its small primary tumor size, MCC has a high propensity for lymph node metastasis and distant spread. Treatment involves wide surgical excision with sentinel lymph node biopsy, often followed by radiation therapy. For advanced or metastatic MCC, checkpoint immunotherapy (avelumab or pembrolizumab) has shown remarkable response rates, transforming outcomes for this disease.

Common Symptoms of Merkel Cell Carcinoma

Recognizing the signs of Merkel Cell Carcinoma early can lead to faster diagnosis and better outcomes. Symptoms may vary in severity from person to person. If you or a loved one are experiencing any of the following, consider speaking with a specialist.

  • A firm, painless, dome-shaped nodule on the skin
  • Rapidly growing skin lesion, often red, blue, or purple
  • Usually appears on sun-exposed areas (head, neck, arms)
  • Nodule may be shiny and flesh-colored to red
  • Rarely causes pain or itching in early stages
  • May be mistaken for a cyst or other benign skin growth

Who Merkel Cell Carcinoma Affects

Primarily affects older adults (median age at diagnosis ~75-80 years), with strong association with chronic sun exposure and fair skin. Significantly more common in immunosuppressed individuals (organ transplant recipients, HIV patients, chronic lymphocytic leukemia patients). About 3-5 times more common in men than women. Merkel cell polyomavirus (MCPyV) is found in ~80% of tumors.

Find Your Next Step

Answer a few questions and we'll point you to the right tools and information for where you are right now.

Where are you in your Merkel Cell Carcinoma journey?

FDA-Approved Treatments for Merkel Cell Carcinoma

There is currently 1 FDA-approved medication for Merkel Cell Carcinoma. These therapies represent the current standard of care and may be used alongside or compared against investigational treatments in active clinical trials.

retifanlimab-dlwr
Incyte
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Ask about these treatments
Type your own question with a little about your situation, and get an answer with sources.
Tap to start:
Or start with one of these

Help Paying for Merkel Cell Carcinoma Treatment

Charity funds and drugmaker programs for Merkel Cell Carcinoma, checked at the source. Pick your insurance to see what fits.

Your insurance
Charity funds

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on September 28, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Open the full patient assistance finder →

Side Effect Explorer

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Questions about side effects?
I can help you understand what these reports mean
Tap to start:
Or start with one of these

Diagnosis and Testing

About 70 to 80% of US cases are driven by clonally integrated Merkel cell polyomavirus and the rest by UV damage; no inherited gene test has a diagnostic role.

Trusted Merkel Cell Carcinoma Resources

Reputable organizations and medical references for learning more about Merkel Cell Carcinoma, including disease registries, foundation resources, and clinical guidelines.

Active Clinical Trials for Merkel Cell Carcinoma

Use this Merkel Cell Carcinoma clinical trial finder to see the 19 studies recruiting patients and 1 opening soon in the United States and worldwide, with eligibility criteria in plain English. These studies play a critical role in advancing care for rare cancers conditions and may offer access to treatments not yet widely available. Each trial below is sourced directly from ClinicalTrials.gov, with eligibility criteria translated into plain English to help patients and caregivers evaluate whether a study may be a fit.

TrialsSite mapPipeline timeline

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

42 active trials worldwide
Filter:
Sort:
NOT YET RECRUITINGPHASE1, PHASE2Recently updatedNCT07472322

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

Intervention: ASTX727 + retifanlimab

Sponsor: University of Wisconsin, Madison

The goal of this clinical trial is to learn if ASTX727 can be combined with retifanlimab to treat Merkel cell cancer. It will also learn about the safety of combining these drugs. The main questions it aims to answer are:

Ages 18 Years+1 location
Started Oct 2026Updated todayEst. May 2031 (~4y 8m)
RECRUITINGPHASE2Recently updatedNCT05583708

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Intervention: Pembrolizumab, Lutetium Lu 177 dotatate

Sponsor: Weill Medical College of Cornell University

The purpose of this study is to find out what effects an immunotherapy drug, called pembrolizumab, combined with a radioactive drug, called lutetium Lu 177 dotatate (Lutathera®) have on patients with Merkel cell carcinoma. Pembrolizumab works by helping patient's immune system to...

Ages 18 Years+4 locations
Started Aug 2023Updated 4 days agoEst. Dec 2028 (~2y 3m)
RECRUITINGPHASE1, PHASE2Recently updatedNCT06047379

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Intervention: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab

Sponsor: Neonc Technologies, Inc.

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma ID...

Ages 18 Years+8 locations
Started Nov 2023Updated 5 days agoEst. Feb 2027 (~5 months)
RECRUITINGPHASE1, PHASE2Recently updatedNCT06814496

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Intervention: Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy

Sponsor: University of Arizona · Amgen

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites.

Ages 18 Years – 99 Years3 locations
Started Sep 2025Updated 1 week agoEst. May 2030 (~3y 8m)
RECRUITINGPHASE1Recently updatedNCT07006727

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Intervention: 225Ac-ETN029, 111In-ETN029

Sponsor: Novartis Pharmaceuticals

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.

Ages 18 Years – 100 Years8 locations
Started Oct 2025Updated 1 week agoEst. Aug 2031 (~4y 11m)
Get trial alerts

Get notified when new Merkel Cell Carcinoma trials open or existing trials change status, add sites, or update eligibility.

We never share your email. Unsubscribe anytime.
Find Merkel Cell Carcinoma trials near you, ranked by distance →
Active trial locations68 cities in the US
+60 more

Trial Pipeline

Jan 2021 to Sep 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Observational
RecruitingOpening soonDelayed startTodayHover a bar for trial details
Need help understanding these trials?
Type your own question with a little about your situation, and get an answer with sources.
Tap to start:
Or start with one of these
Run a Merkel Cell Carcinoma foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Patient Communities

Connect with other Merkel Cell Carcinoma patients, caregivers, and advocacy groups across Facebook groups, Reddit communities, and YouTube channels. These patient communities offer peer support, shared experiences, caregiver resources, and real-time discussion about Merkel Cell Carcinoma treatments, clinical trial participation, and day-to-day disease management.

Find the right community
Type your own question with a little about your situation, and get an answer with sources.
Tap to start:
Or start with one of these

Related Rare Cancers Conditions

Other rare diseases in the rare cancers category. Patients with Merkel Cell Carcinoma may find relevant research, shared treatment pathways, or overlapping clinical trials among these related conditions.

Companies Developing Merkel Cell Carcinoma Treatments

10 pharmaceutical companies have Merkel Cell Carcinoma in their rare disease portfolio

Frequently Asked Questions About Merkel Cell Carcinoma